Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Cardiology · Familial Combined Hyperlipidemia

Building Your Treatment Plan: Standard Care for FCHL

At a Glance

Familial combined hyperlipidemia is treated with a risk-based plan that combines heart-healthy habits with statins when indicated. Additional medicines can lower cholesterol or triglycerides, while very high triglycerides need treatment to help prevent pancreatitis.

Because Familial Combined Hyperlipidemia (FCHL) involves both high cholesterol and high triglycerides, treatment is driven by your overall risk of Atherosclerotic Cardiovascular Disease (ASCVD) and your specific lipid pattern [1][2].

While LDL-C is a central, guideline-established treatment target, modern guidelines emphasize using Apolipoprotein B (ApoB) and Non-HDL Cholesterol (Non-HDL-C) alongside it [3]. These markers provide a more comprehensive count of all the atherogenic particles in your blood, which is vital because standard LDL tests can be imprecise when triglycerides are elevated [4][5].

Step 1: Lifestyle and Foundations

Before or alongside medication, lifestyle changes are the foundation of FCHL management, though they should not delay indicated pharmacotherapy when inherited lipid exposure is high [6].

  • Nutrition: Shifting toward a heart-healthy dietary pattern that replaces saturated fats and refined starches/sugars with fiber-rich foods [7][6].
  • Alcohol Management: Reducing or avoiding alcohol is often necessary if triglycerides are high, as alcohol can trigger sharp spikes in fat levels [7].
  • Physical Activity & Other Risks: Aiming for daily physical activity helps improve insulin sensitivity. Addressing smoking cessation, blood pressure, and sleep apnea is also critical [6][8].

Step 2: First-Line Medication (Statins)

For most people requiring ASCVD risk reduction, a statin is the cornerstone of lipid-lowering therapy [1]. Statins work by slowing down cholesterol production in the liver and helping the liver clear existing particles from the blood [9]. They are highly effective at reducing the overall number of ApoB particles and lowering the risk of heart attacks [10][11].

Patient Safety Guardrails: Statins are generally well-tolerated. However, you should contact your clinician if you experience severe, unexplained muscle weakness or unusually dark urine. Additionally, statins are generally avoided during pregnancy unless a specialist advises otherwise; discuss family planning with your doctor.

Step 3: Add-On Therapies for Cholesterol

If a maximally tolerated statin does not bring your LDL-C, ApoB, or Non-HDL-C to your risk-based target, your doctor may add secondary treatments:

  • Ezetimibe: This medication prevents cholesterol from being absorbed in the intestine. It is frequently the first “add-on” to a statin [12][13].
  • PCSK9 Inhibitors: Injectable medications (like evolocumab or alirocumab) that dramatically increase the liver’s ability to clear LDL and ApoB particles [10][14]. They are generally reserved for patients at very high risk (such as those with established heart disease) or those who cannot reach their goals on other drugs [15].
  • Other Options: Medications like bempedoic acid or inclisiran may also be used depending on ASCVD history, cost/access, and local indications [16][17].

Step 4: Managing Elevated Triglycerides

Treating triglycerides depends heavily on the level of elevation and the clinical goal:

  • Triglycerides 150–499 mg/dL: Clinicians generally first address secondary causes, optimize statin therapy, and manage lifestyle/diabetes. In highly selected high-risk populations, a specific prescription omega-3 (icosapent ethyl) has cardiovascular-outcome evidence for reducing heart events [18][19]. (Note: Over-the-counter fish oil supplements are not equivalent).
  • Triglycerides > 500 mg/dL: The immediate goal is often preventing acute pancreatitis. In these cases, your doctor may prescribe fibrates (like fenofibrate) [20][21]. Fibrates require careful medical supervision, especially when combined with statins (particularly gemfibrozil), due to increased risks of drug interactions and the need for renal/hepatic monitoring.

Managing the Whole Picture

Treating FCHL also means keeping a close eye on your blood sugar (HbA1c) and liver health. Because FCHL patients have a higher risk of developing Type 2 diabetes, periodic screening is a standard part of follow-up care [22]. By managing these “partner” conditions alongside your lipids, you can more effectively lower your overall cardiovascular risk [23][24].

What to Expect: Your clinician will typically repeat your lipid panel 4 to 12 weeks after starting or changing a medication to assess your response and adjust doses if necessary.

Common questions in this guide

What is the usual starting treatment for FCHL?
Treatment usually starts with heart-healthy eating, regular physical activity, and management of alcohol intake and other cardiovascular risks. When medication is indicated, a statin is generally the first-line treatment to reduce harmful cholesterol particles and heart risk. Lifestyle changes should not delay medication when your clinician recommends it.
Why are ApoB and non-HDL cholesterol useful in FCHL?
ApoB and non-HDL cholesterol provide information about the total number of cholesterol-carrying particles that can contribute to artery disease. They are useful alongside LDL cholesterol because an LDL result may be less precise when triglycerides are high. Your clinician can use these results with your overall cardiovascular risk to set targets.
What medicines may be added if a statin is not enough?
Ezetimibe is often the first add-on medicine when a statin does not reach the cholesterol goal. Injectable PCSK9 inhibitors can help the liver clear more cholesterol particles, while bempedoic acid or inclisiran may be options for some patients. The choice depends on cardiovascular history, response, tolerability, cost, access, and local indications.
How is treatment chosen when triglycerides are high?
For triglycerides of 150 to 499 mg/dL, clinicians usually look for secondary causes, optimize statin and lifestyle treatment, and manage blood sugar; selected high-risk patients may receive icosapent ethyl. Over-the-counter fish oil is not equivalent to this prescription treatment. When triglycerides are above 500 mg/dL, the immediate goal may be preventing pancreatitis, and a fibrate may be prescribed with careful supervision.
When should my cholesterol be checked after starting or changing medicine?
A lipid panel is typically repeated 4 to 12 weeks after starting or changing a lipid-lowering medicine. The results show how well treatment is working and help your clinician adjust the dose or add another treatment.
What statin side effects should prompt me to contact my clinician?
Statins are generally well tolerated, but severe unexplained muscle weakness or unusually dark urine should prompt prompt contact with your clinician. Statins are generally avoided during pregnancy unless a specialist advises otherwise, so discuss pregnancy plans before treatment.
Why are blood sugar and liver health monitored in FCHL?
Follow-up may include HbA1c and liver-health monitoring because people with FCHL have a higher risk of type 2 diabetes and may have insulin resistance or steatotic liver disease. Monitoring helps identify related problems and guide the treatment plan.

Get notified when new evidence is published on hyperlipidemia, familial combined, LPL related.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (24)
  1. 1

    FAMILIAL COMBINED HYPERLIPIDEMIA: CURRENT KNOWLEDGE, PERSPECTIVES, AND CONTROVERSIES.

    Bello-Chavolla OY, Kuri-García A, Ríos-Ríos M, et al.

    Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 2018; (70(5)):224-236 doi:10.24875/RIC.18002575.

    PMID: 30307446
  2. 2

    Familial combined hyperlipidaemia/polygenic mixed hyperlipidaemia.

    Pedro-Botet J, Climent E, Gabarró N, Millán J

    Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis 2021; (33 Suppl 2()):43-49 doi:10.1016/j.arteri.2020.12.013.

    PMID: 34006353
  3. 3

    How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL.

    Averna M, Stroes E,

    Atherosclerosis. Supplements 2017; (26()):16-24 doi:10.1016/S1567-5688(17)30021-1.

    PMID: 28434480
  4. 4

    Is the Commitment to LDL-C Eternal?

    Sniderman AD

    Methodist DeBakey cardiovascular journal 2026; (22(4)):15-21 doi:10.14797/mdcvj.1845.

    PMID: 42761924
  5. 5

    Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group.

    Wilson PWF, Jacobson TA, Martin SS, et al.

    Journal of clinical lipidology 2021; (15(5)):629-648 doi:10.1016/j.jacl.2021.09.046.

    PMID: 34802986
  6. 6

    Does lifestyle contribute to disease severity in patients with inherited lipid disorders?

    Arsenault BJ, Perrot N, Couture P

    Current opinion in lipidology 2017; (28(2)):177-185 doi:10.1097/MOL.0000000000000387.

    PMID: 28030378
  7. 7

    Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association.

    Kirkpatrick CF, Sikand G, Petersen KS, et al.

    Journal of clinical lipidology 2023; (17(4)):428-451 doi:10.1016/j.jacl.2023.05.099.

    PMID: 37271600
  8. 8

    Cholesterol oversynthesis markers define familial combined hyperlipidemia versus other genetic hypercholesterolemias independently of body weight.

    Baila-Rueda L, Cenarro A, Lamiquiz-Moneo I, et al.

    The Journal of nutritional biochemistry 2018; (53()):48-57 doi:10.1016/j.jnutbio.2017.10.005.

    PMID: 29190549
  9. 9

    Hypertriglyceridemia and omega-3 fatty acids: Their often overlooked role in cardiovascular disease prevention.

    Arca M, Borghi C, Pontremoli R, et al.

    Nutrition, metabolism, and cardiovascular diseases : NMCD 2018; (28(3)):197-205 doi:10.1016/j.numecd.2017.11.001.

    PMID: 29397253
  10. 10

    Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update.

    Kaddoura R, Orabi B, Salam AM

    Journal of drug assessment 2020; (9(1)):129-144 doi:10.1080/21556660.2020.1801452.

    PMID: 32939318
  11. 11

    PCSK9 inhibitors: clinical evidence and implementation.

    Sabatine MS

    Nature reviews. Cardiology 2019; (16(3)):155-165 doi:10.1038/s41569-018-0107-8.

    PMID: 30420622
  12. 12

    Familial Hypercholesterolaemia Diagnosis and Management.

    Alonso R, Perez de Isla L, Muñiz-Grijalvo O, et al.

    European cardiology 2018; (13(1)):14-20 doi:10.15420/ecr.2018:10:2.

    PMID: 30310464
  13. 13

    An updated review of lipid-modifying therapy.

    Simons LA

    The Medical journal of Australia 2019; (211(2)):87-92 doi:10.5694/mja2.50142.

    PMID: 31006138
  14. 14

    Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.

    Rosenson RS, Jacobson TA, Preiss D, et al.

    Cardiovascular drugs and therapy 2016; (30(3)):305-13 doi:10.1007/s10557-016-6666-1.

    PMID: 27240673
  15. 15

    Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience.

    Alonso R, Muñiz-Grijalvo O, Díaz-Díaz JL, et al.

    Journal of clinical lipidology 2021; (15(4)):584-592 doi:10.1016/j.jacl.2021.04.011.

    PMID: 34052174
  16. 16

    Current and Future Perspectives of LDL-C Lowering Therapies 2026.

    Tada H, Sakata K, Usui S, Takamura M

    Journal of atherosclerosis and thrombosis 2026; (33(9)):1111-1123 doi:10.5551/jat.RV22052.

    PMID: 42203447
  17. 17

    Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.

    Raal FJ, Kallend D, Ray KK, et al.

    The New England journal of medicine 2020; (382(16)):1520-1530 doi:10.1056/NEJMoa1913805.

    PMID: 32197277
  18. 18

    Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.

    Skulas-Ray AC, Wilson PWF, Harris WS, et al.

    Circulation 2019; (140(12)):e673-e691 doi:10.1161/CIR.0000000000000709.

    PMID: 31422671
  19. 19

    Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides.

    Pareek M, Mason RP, Bhatt DL

    Expert opinion on drug safety 2022; (21(1)):31-42 doi:10.1080/14740338.2021.1954158.

    PMID: 34253137
  20. 20

    Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.

    Ito MK

    Atherosclerosis 2015; (242(2)):647-56.

    PMID: 26296750
  21. 21

    Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention.

    Quispe R, Sweeney T, Varma B, et al.

    Current atherosclerosis reports 2022; (24(10)):767-778 doi:10.1007/s11883-022-01052-4.

    PMID: 35895246
  22. 22

    Incidence of type 2 diabetes in familial combined hyperlipidemia.

    Brouwers MCGJ, de Graaf J, Simons N, et al.

    BMJ open diabetes research & care 2020; (8(1)) doi:10.1136/bmjdrc-2019-001107.

    PMID: 32193201
  23. 23

    Lipoprotein(a) in familial dyslipidemias: The effect on cardiovascular prognosis in patients with familial hypercholesterolemia or familial combined hyperlipidemia.

    Skoumas I, Andrikou I, Simantiris S, et al.

    Nutrition, metabolism, and cardiovascular diseases : NMCD 2025; (35(7)):103867 doi:10.1016/j.numecd.2025.103867.

    PMID: 39986939
  24. 24

    Fatty Liver as Potential Biomarker of Atherosclerotic Damage in Familial Combined Hyperlipidemia.

    Mandraffino G, Morace C, Franzè MS, et al.

    Biomedicines 2022; (10(8)) doi:10.3390/biomedicines10081770.

    PMID: 35892670

This page is for informational purposes only and does not constitute medical advice. Your clinician should set your lipid targets and choose treatment based on your cardiovascular risk, triglyceride level, and other health conditions.

Guide contents hyperlipidemia, familial combined, LPL related
Research & Literature
03 Cardiovascular Risks and Metabolic Health in FCHL 05 Monitoring and Building Your Care Team